Scientific Program Committee

Tuesday
February 5 Sessions
Session 26 CROI 2008
c Tuesday, 1-4 pm; Poster Hall
Poster Abstracts
(see full session listings starting on page 25)
Session 49. New Insights into APOBEC Proteins
Session 50. Viral Replication Cycle: Molecular Studies
Session 51. Viral Envelope: Tropism and Co-receptor Studies
Session 52. Viral Fitness, Evolution and Recombination
Session 60. CTL Studies and Consequences of Immune Escape
Session 61. Factors Influencing CD4 Counts
Session 62. HIV Superinfection and Viral Co-infection
Session 69. Virologic Parameters in NeuroAIDS
Session 70. Studies into Mechanisms of HIV Neuropathogenesis
Session 75. Immune Activation and Lymphocyte Function
Session 76. Studies on Regulatory T Cells
Session 77. Immune Responses and Control of Viremia
Session 88. New Approaches to HIV Testing
Session 92. HIV-1 Prevention for Positives
Session 93. Modeling the Cost-effectiveness and Impact of PrEP on Resistance
Session 98. Complications, Neurodevelopment and ART-related Toxicities in
Children
Session 99. Mycobacterial Disease in Children
Session 100. Prevention, Identification and Treatment of at-Risk and HIV-infected
Adolescents
Session 107. Maternal ART and Feeding Practices: Impact on Infant Outcomes
Session 108. Infant Feeding, PMTCT and Infant Outcome
Session 109. Properties of Breast Milk
Session 114. Influence of Gender on HIV Replication and Viremia
Session 115. HIV Replication, Immune Activation, HIV-2 Co-infection, and
Genital Shedding in Women
Session 123. ART: Novel Approaches I
Session 124. ART: Novel Approaches II
Session 125. Clinical Pharmacology of Reverse Transcriptase Inhibitors
Session 126. Clinical Pharmacology of Protease Inhibitors
Session 132. Switching Therapy/Treatment Failure in Scale-up Programs
Session 136. Resistance to New Antiretrovirals
Session 137. Emerging Patterns of Resistance to New Antiretrovirals
Session 138. Minor Drug-resistant Variants: Detection and Clinical Significance
Session 149. Impact of Subtype on HIV Quantification
Session 150. New Diagnostic and Monitoring Tools
Session 155. Hepatic Complications
Session 156. Markers of Inflammation, Immunodeficiency and Complications
Session 157. Changes in Bone Mineral Density
Session 158. Renal Disease
Session 172. Hepatitis C Co-infection: Markers, Outcome and Effect of ART
Session 173. Hepatitis C Co-infection: Treatment
Session 174. Hepatitis Co-infection: Cardiovascular and Malignancy Association
14 15th Conference on Retroviruses and Opportunistic Infections
c Tuesday, 2-3 pm; Room 311
CME
Session 26–Poster Discussion
(see Session 68 on Monday for corresponding Poster Abstracts)
Clinical Developments in Neuropathogenesis
Discussants:
Dennis Kolson, Univ of Pennsylvania, Philadelphia, US
Richard Price, Univ of California, San Francisco, US
391 Changes in Cognition during HAART: Comparison of 2
Different Scoring Systems to Measure Antiretroviral Drug
Efficacy on HIV Dementia
Valerio Tozzi*, P Balestra, M Salvatori, C Vlassi, G Liuzzi, S Menichetti,
M Zaccarelli, S Cerilli, A Antinori, and P Narciso
Natl Inst for Infectious Diseases “Lazzaro Spallanzani”, Rome, Italy
392 CSF Neural Marker Profile Distinguishes AIDS Dementia
Complex from Alzheimer’s Disease
Magnus Gisslen* 1 , K Blennow 1 , B Brew 2 , P Cinque 3 , L Hagberg 1 , R Price 4 ,
and H Zetterberg 1
1 Sahlgrenska Univ Hosp, Gothenburg, Sweden; 2 St Vincent’s Hosp, Univ
of New South Wales, Sydney, Australia; 3 San Raffaele Hosp, Milan, Italy;
and 4 Univ of California, San Francisco, US
393 HIV Protease Inhibitors and Risk of Peripheral Neuropathy
Ronald Ellis* 1 , J Marquie-Beck 1 , P Delaney 1 , T Alexander 1 , D Clifford 2 ,
J McArthur 3 , D Simpson 4 , C Ake 1 , A Collier 5 , B Gelman 6 , and the
CHARTER Group
1 Univ of California, San Diego, US; 2 Washington Univ, St Louis, MO, US;
3 Johns Hopkins Univ, Baltimore, MD, US; 4 Mt Sinai Sch of Med, New
York, NY, US; 5 Univ of Washington, Seattle, US; and 6 Univ of Texas Med
Branch, Galveston, US
394 ART Resistance Influences CSF HIV RNA Levels and
Neuropsychological Performance in HIV-infected Individuals
George Hightower* 1 , S Letendre 1 , M Cherner 1 , S Gibson 1 , R Ellis 1,2 ,
C Ignacio 1 , R Heaton 1 , I Grant 1,2 , D Richman 1,2 , D Smith 1,2 , and San Diego
HIV Neurobehavioral Res Ctr (HNRC) Group
1 Univ of California, San Diego, US and 2 San Diego VA Hlthcare Systems,
CA, US
395 CSF t-τ/p-τ and Amyloid-β 1-42 in HIV Infection
Bruce Brew* 1 , M Gisslen 2 , L Pemberton 1 , P Cinque 3 , L Hagberg 2 , R Price 4 ,
K Blennow 2 , H Zetterberg 2 , and S Spudich 4
1 St Vincent’s Hosp, Sydney Australia; 2 Gothenburg Univ, Sweden; 3 San
Raffaele Hosp, Milan, Italy; and 4 Univ of California, San Francisco, US
396a Comparative Analysis of HIV-specific CD8 + T Cells
in Cerebrospinal Fluid and Peripheral Blood among
Treatment-naïve HIV-immune Controllers
Shanmugalakshmi Sadagopal*, S Lorey, L Barnett, R Basham, L Lebo,
H Erdem, K Haman, M Avison, D Haas, and S Kalams
Vanderbilt Univ, Nashville, TN, US
396b Abnormal CSF Amyloid β42 Levels Link HIV-associated
Cognitive Disease and Alzheimer’s Disease
David Clifford*, J Kauwe, M Teshome, A Shah, M Spinner, J Morris,
D Holtzman, and A Fagan
Washington Univ, St Louis, MO, US